Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Non Inferiority KawasakI Trial With Anakinra
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Meyer Children's Hospital IRCCS
- Target Recruit Count
- 38
- Registration Number
- NCT06697431
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 3
- Registration Number
- NCT06666335
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT06624436
- Locations
- 🇳🇱
Intensive Care Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2000
- Registration Number
- NCT06381661
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06336733
- Locations
- 🇫🇷
Service de Médecine interne Hopital Tenon, Paris, France
Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 20
- Registration Number
- NCT06071156
- Locations
- 🇮🇹
CCPC, Ancona, Marche, Italy
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 20
- Registration Number
- NCT06062966
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 20
- Registration Number
- NCT05854251
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 15
- Registration Number
- NCT05814159
- Locations
- 🇯🇵
Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan
🇯🇵Yokohama City University Hospital (pediatrics), Yokohama, Kanagawa, Japan
🇯🇵Saitama Prefectural Children's Medical Center, Saitama-shi, Saitama, Japan
Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Istituto Giannina Gaslini
- Target Recruit Count
- 48
- Registration Number
- NCT05805930
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.